Radial Artery Injury, Hematoma, Bleed
Conditions
Brief summary
In 2008 Goker et al, introduced Ankaferd Blood Stopper (ABS) as a new hemostatic drug. Recently, ABS has been shown to produce local hemostasis by implementing topically after major arterial vessel injury. Reducing the compression time during patent hemostasis by facilitating hemostasis may decrease RAO. To test this hypothesis the investigators planned a three arm randomized study to evaluate the safety and efficacy of Ankaferd blood stopper in adjunct to short-time compression, compared to either short-time compression with conventional sterile gauzes or with a TR band after transradial diagnostic procedures.
Sponsors
Acibadem University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* All consecutive patients undergoing transradial elective diagnostic coronary procedures between November 2016 and November 2017 at the catheterization laboratory of Acibadem University Kocaeli Hospital were considered to be enrolled in the study.
Exclusion criteria
* The only
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Radial artery occlusion assessed by reverse Barbeau's test | 24 hours |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Bleeding | 2 hours | any kind of bleeding defined as ml after the removal of hemostatic dressings or devices |
| Hematoma | 24 hours | hematomas larger then \>5cm |
Countries
Turkey (Türkiye)
Contacts
Primary ContactSevket Gorgulu, Prof
Outcome results
None listed